Business
Cardiff Oncology Announces Upcoming Presentation on Lead KRAS-mutated Metastatic Colorectal Cancer Program at the 2022 American Society of Clinical Oncology Gastrointestinal Cancers Symposium
SAN DIEGO, Dec. 10, 2021 /PRNewswire/ -- Cardiff Oncology, Inc. (Nasdaq: CRDF), a clinical-stage oncology company, developing new precision medicine treatment
About this update from Cardiff Oncology, Inc.
[{"type":"text","content":"SAN DIEGO, Dec. 10, 2021 /PRNewswire/ -- Cardiff Oncology, Inc. (Nasdaq: CRDF), a clinical-stage oncology company, developing new precision medicine treatment options for cancer patients in indications with the greatest unmet medical need including KRAS-mutated colorectal cancer, pancreatic cancer, and castrate-resistant prostate cancer, today announced that updated data from its lead KRAS-mutated metastatic colorectal cancer program will be featured in a poster presentation at the American Society of Clinical Oncology Gastrointestinal Cancers Symposium (ASCO-GI). ASCO-GI is taking place January 20-22, 2022, both virtually and in-person at the Moscone West Building in San Francisco, California. \n\n \n \n \n \n \n \n\n \nDetails on the poster and its corresponding abstract can be found below. \nTitle:\nA phase 1b/2 trial of the PLK1 inhibitor onvansertib in combination with FOLFIRI-bev in 2L treatment of KRAS-mutated (mKRAS) metastatic colorectal carcinoma (mCRC)\nAbstract Number:\n100\nAbstract Publication Date:\nJanuary 18, 2022\nAbstract Publication Time:\n5:00 PM ET\nPoster Session Name:\nPoster Session C: Cancers of the Colon, Rectum, and Anus\nPoster Session Date:\nJanuary 22, 2022\nPoster Session Time:\n9:30 AM – 10:55 AM ET \nPoster Session Location:\nLevel 1, West Hall (and online)\nA copy of the poster will be available on the \"Scientific Presentations\" section of the Cardiff Oncology website at https://cardiffoncology.com/scientific-presentations/ following its presentation at the meeting. \nAbout Cardiff Oncology, Inc.Cardiff Oncology is a clinical-stage oncology company, developing new precision medicine treatment options for cancer patients in indications with the greatest unmet medical need. Our goal is to target tumor vulnerabilities with treatment combinations that overcome disease resistance and improve disease response to standard treatment regimens and to increase overall survival. We are developing onvansertib, a first-in-class, third-generation Polo-like Kinase 1 (\"PLK1\") inhibitor, in combination with standard-of-care anti-cancer therapeutics. Our clinical development programs incorporate tumor genomics and biomarker technology to refine assessment of patient response to treatment. We have three clinical programs currently ongoing: a Phase 1b/2 study of onvansertib in combination with FOLFIRI/Avastin® ...